Fig 2: Gastric cancer patients’ disease-specific survival by subgroup according to the Kaplan–Meier method, with p values for significance based on the log-rank test. A high versus a low TLR5 expression amongst patients with (A) stage II disease, (B) an intestinal-, and (C) a diffuse-type cancer. A high versus a low TLR7 expression amongst patients with (D) stage I and (E) stage III disease. (F) A high versus a low TLR9 expression amongst patients with stage II disease.

Fig 3: TLR5 and TLR7 expression in nasopharyngeal carcinoma and in the normal epithelium. a H&E staining in non-keratinizing undifferentiated carcinoma (NK-U). b H&E staining in keratinizing squamous cell carcinoma (KSCC). c Mild positive TLR5 expression in NK-U. d Strong positive TLR5 expression in KSCC. e Moderate positive TLR7 expression in NK-U. f Moderate positive TLR7 expression in KSCC. g Positive TLR5 staining in benign nasopharyngeal epithelium. h Positive TLR7 staining in benign nasopharyngeal epithelium. Magnification × 250

Fig 4: Kaplan-Meier survival curves. a Overall survival for TLR5. b Disease-specific survival for TLR5. c Overall survival for TLR7. d Disease-specific survival for TLR7

Fig 5: Gastric cancer patients’ disease-specific survival according to the Kaplan–Meier method, with p values for significance based on the log-rank test. High (A) TLR1, (B) TLR2, (C) TLR4, (D) TLR5, (E) TLR7, and (F) TLR9 expressions compared to low expressions.